138 related articles for article (PubMed ID: 32524416)
1. Comparable Incidence of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir.
Shin JW; Jeong J; Jung SW; Lee SB; Park BR; Kim MJ; Park EJ; Park NH
Dig Dis Sci; 2021 May; 66(5):1739-1750. PubMed ID: 32524416
[TBL] [Abstract][Full Text] [Related]
2. Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir- vs. entecavir-based regimens: Individual patient data meta-analysis.
Choi WM; Yip TC; Wong GL; Kim WR; Yee LJ; Brooks-Rooney C; Curteis T; Cant H; Chen CH; Chen CY; Huang YH; Jin YJ; Jun DW; Kim JW; Park NH; Peng CY; Shin HP; Shin JW; Yang YH; Lim YS
J Hepatol; 2023 Mar; 78(3):534-542. PubMed ID: 36572349
[TBL] [Abstract][Full Text] [Related]
3. Differential Effectiveness of Tenofovir and Entecavir for Prophylaxis of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Depending on Coexisting Cirrhosis and Prior Exposure to Antiviral Therapy: A Systematic Review and Meta-analysis.
Jeong S; Cho Y; Park SM; Kim W
J Clin Gastroenterol; 2021 Oct; 55(9):e77-e86. PubMed ID: 33883516
[TBL] [Abstract][Full Text] [Related]
4. Entecavir versus tenofovir on the recurrence of hepatitis B-related HCC after liver transplantation: A multicenter observational study.
Kim DG; Choi Y; Rhu J; Hwang S; You YK; Kim DS; Nah YW; Kim BW; Cho JY; Kang KJ; Yang JD; Choi D; Joo DJ; Kim MS; Ryu JH; Lee JG;
Liver Transpl; 2023 Dec; 29(12):1272-1281. PubMed ID: 37489922
[TBL] [Abstract][Full Text] [Related]
5. Lower risk of hepatocellular carcinoma with tenofovir than entecavir in antiviral treatment-naïve chronic hepatitis B patients: a systematic review and meta-analysis involving 90,897 participants.
Shao J; Wang Y; Hu L; Zhang L; Lyu C
Clin Exp Med; 2023 Oct; 23(6):2131-2140. PubMed ID: 36648567
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of switching from tenofovir disoproxil fumarate to tenofovir alafenamide versus entecavir for chronic hepatitis B patients in Greece.
Sinakos E; Kachru N; Tsoulas C; Jeyakumar S; Smith NJ; Yehoshua A; Cholongitas E
J Comp Eff Res; 2024 Apr; 13(4):e230090. PubMed ID: 38317634
[No Abstract] [Full Text] [Related]
7. Personalized Antiviral Drug Selection in Patients With Chronic Hepatitis B Using a Machine Learning Model: A Multinational Study.
Hur MH; Park MK; Yip TC; Chen CH; Lee HC; Choi WM; Kim SU; Lim YS; Park SY; Wong GL; Sinn DH; Jin YJ; Kim SE; Peng CY; Shin HP; Chen CY; Kim HY; Lee HA; Seo YS; Jun DW; Yoon EL; Sohn JH; Ahn SB; Shim JJ; Jeong SW; Cho YK; Kim HS; Jang MJ; Kim YJ; Yoon JH; Lee JH
Am J Gastroenterol; 2023 Nov; 118(11):1963-1972. PubMed ID: 36881437
[TBL] [Abstract][Full Text] [Related]
8. Tenofovir versus entecavir on the prognosis of hepatitis B-related hepatocellular carcinoma after surgical resection: a randomised controlled trial.
Linye H; Zijing X; Xiaoyun Z; Zhihui L; Tianfu W; Chuan L
Int J Surg; 2023 Oct; 109(10):3032-3041. PubMed ID: 37335984
[TBL] [Abstract][Full Text] [Related]
9. Effects of entecavir and tenofovir disoproxil fumarate on the incidence and severity of COVID-19 in patients with chronic hepatitis B.
Liao X; Fan Y; Zhong C; Zhao S; Guo L; Tan W; Yin J; Fan R
BMC Infect Dis; 2023 Nov; 23(1):843. PubMed ID: 38036959
[TBL] [Abstract][Full Text] [Related]
10. The effect of switch therapy to tenofovir versus entecavir maintenance on recurrence of hepatocellular carcinoma after surgery (SWITE): study protocol for a randomized controlled trial.
Peng W; Yi M; Qi X; Qi W; Li C; Wen T
Trials; 2023 Dec; 24(1):781. PubMed ID: 38042834
[TBL] [Abstract][Full Text] [Related]
11. Aspirin Reduces the Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Receiving Oral Nucleos(t)ide Analog.
Hui VW; Yip TC; Wong VW; Tse YK; Chan HL; Lui GC; Wong GL
Clin Transl Gastroenterol; 2021 Mar; 12(3):e00324. PubMed ID: 33750746
[TBL] [Abstract][Full Text] [Related]
12. A machine learning model for predicting hepatocellular carcinoma risk in patients with chronic hepatitis B.
Lee HW; Kim H; Park T; Park SY; Chon YE; Seo YS; Lee JS; Park JY; Kim DY; Ahn SH; Kim BK; Kim SU
Liver Int; 2023 Aug; 43(8):1813-1821. PubMed ID: 37452503
[TBL] [Abstract][Full Text] [Related]
13. Renal safety of tenofovir disoproxil fumarate and entecavir in liver transplant patients: a nationwide Korean registry study.
Lee J; Lee JG; Hwang S; Lee KW; Kim JM; Ryu JH; Kim BW; Choi DL; You YK; Kim DS; Nah YW; Kang KJ; Cho JY; Yu HC; Hong G; Choi D; Moon JI; Kim MS
Hepatol Int; 2022 Jun; 16(3):537-544. PubMed ID: 35467324
[TBL] [Abstract][Full Text] [Related]
14. Mortality in patients with chronic hepatitis B treated with tenofovir or entecavir: A multinational study.
Jang TY; Liang PC; Jun DW; Jung JH; Toyoda H; Wang CW; Yuen MF; Cheung KS; Yasuda S; Kim SE; Yoon EL; An J; Enomoto M; Kozuka R; Chuma M; Nozaki A; Ishikawa T; Watanabe T; Atsukawa M; Arai T; Hayama K; Ishigami M; Cho YK; Ogawa E; Kim HS; Shim JJ; Uojima H; Jeong SW; Ahn SB; Takaguchi K; Senoh T; Buti M; Vargas-Accarino I E; Abe H; Takahashi H; Inoue K; Yeh ML; Dai CY; Huang JF; Huang CF; Chuang WL; Nguyen MH; Yu ML
J Gastroenterol Hepatol; 2024 Mar; ():. PubMed ID: 38480009
[TBL] [Abstract][Full Text] [Related]
15. The Risk of Hepatocellular Carcinoma in Entecavir Versus Tenofovir Treated US Cohort With Chronic Hepatitis B Virus.
Kramer JR; Richardson PA; Kim H; Hsu YC; Kanwal F; El-Serag HB
Clin Gastroenterol Hepatol; 2023 Apr; 21(4):1111-1113.e3. PubMed ID: 35276326
[TBL] [Abstract][Full Text] [Related]
16. Five-year on-treatment variables-based PPACS model predicts subsequent hepatocellular carcinoma in entecavir/tenofovir-treated patients.
Ha Y; Lim J; Chon YE; Kim MN; Lee JH; Kim KM; Shim JH; Lee D; Hwang SG; Han S; Lee HC
Int J Cancer; 2023 Dec; 153(12):2045-2054. PubMed ID: 37615539
[TBL] [Abstract][Full Text] [Related]
17. Noninferiority Outcomes of Besifovir Compared to Tenofovir Alafenamide in Treatment-Naïve Patients with Chronic Hepatitis B.
Kim TH; Kim JH; Yim HJ; Seo YS; Yim SY; Lee YS; Jung YK; Yeon JE; Um SH; Byun KS
Gut Liver; 2024 Mar; 18(2):305-315. PubMed ID: 38213189
[TBL] [Abstract][Full Text] [Related]
18. Enhanced prognosis of HCC patients undergoing radical treatments with tenofovir versus entecavir: A meta-analysis based on propensity score matching studies.
Kong Q; Yi M; Teng F; Chen Z
Asian J Surg; 2024 Jan; 47(1):55-62. PubMed ID: 37739894
[TBL] [Abstract][Full Text] [Related]
19. Clinical characteristics and outcomes of patients with cirrhosis and hepatocellular carcinoma in The Gambia, west Africa: a prospective cohort study.
Ndow G; Vo-Quang E; Shimakawa Y; Ceesay A; Tamba S; Njai HF; Bojang L; Hateley C; Takao Y; Opoku E; Warsop Z; Ingiliz P; D'Alessandro U; Chemin I; Mendy M; Thursz M; Njie R; Lemoine M
Lancet Glob Health; 2023 Sep; 11(9):e1383-e1392. PubMed ID: 37517420
[TBL] [Abstract][Full Text] [Related]
20. Tenofovir versus Entecavir on Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma After FOLFOX-Hepatic Arterial Infusion Chemotherapy.
Zheng Z; Wang J; Wu T; He M; Wang J; Pan Y; Chen J; Hu D; Xu L; Zhang Y; Chen M; Zhou Z
J Hepatocell Carcinoma; 2023; 10():2117-2132. PubMed ID: 38053944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
